FDA eases black box restrictions for ultrasound contrast media

May 14, 2008 FDA eases black box restrictions for ultrasound contrast media James Brice -------------------------------------------------------------------------------- The FDA has eased off on stringent black box warnings that greatly restricted use in the U.S. of microbubble ultrasound media during echocardiography. An online edition of the Wall Street Journal reported May 13 that the FDA had lowered a ban against the use of Definity, formerly sold by Bristol-Myers Squibb, and Optison, a microbubble agent sold by GE Healthcare, for echocardiography performed on acutely ill patients.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC